The FDA Committee recommends restricting the dosage of Pfizer Booster to the elderly
1 min read
Photo: Myke Sena/MS
FDA Scientific Advisory Committee, “Anvisa of the USA”, Friday (17) recommended the application of a booster dose of the Pfizer vaccine to elderly people aged 65 and over and people at risk of severe symptoms of Covid..
Hours earlier, the same committee had advised against the application of this booster dose by Pfizer by a vote of 16 to 2, for people over 16 years of age. According to the New York Times, there was Intense public discussion About whether a booster vaccine is needed, and if so, who.
In the panel discussion, several independent experts, including infectious disease specialists and statisticians, questioned whether the data justified the additional doses for most of the population at a time when immunization devices still provide strong protection against Covid infection and hospitalization.
“It is unclear whether everyone needs a booster injection, except for a subset of the population who are clearly at risk of developing serious disease.”Dr. Michael J. Corella, MD, a board member and administrator at the National Institutes of Health, said.
While the FDA is not required to adopt its advisory committee’s recommendations, they are usually followed. The agency is expected to make a decision in this regard early next week.
More news
“Devoted food specialist. General alcohol fanatic. Amateur explorer. Infuriatingly humble social media scholar. Analyst.”
